Trillium Therapeutics Inc

TRIL

$18.44

0.0% last 12 months

Market Cap

$0

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$0.00 - $0.00

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $0
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return 0.0%
52-Week High $0.00
52-Week Low $0.00
Beta 0.0
Outstanding Shares 105 Million
Avg 30 Day Volume 0

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

Insider trades

No purchases

20,487 shares sold (3 transactions)

No purchases

23,802 shares sold (1 transactions)

No purchases

3,646 shares sold (1 transactions)

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Trillium Therapeutics Inc

Industry: Biological Product (except Diagnostic) Manufacturing

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

News